New drug aims to thicken nerves and strengthen grip in rare nerve disorder
NCT ID NCT07610564
First seen Jun 27, 2026 · Last updated Aug 14, 2026 · Updated 2 times
Summary
This early-stage trial tests an experimental drug called empasiprubart in 60 adults with multifocal motor neuropathy (MMN), a rare condition that causes muscle weakness. The drug is given as an IV infusion, and researchers will use ultrasound to measure nerve thickness, along with tests of muscle strength and grip. The study is open-label, meaning everyone gets the drug, and participants will be followed for about 29 months.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- empasiprubart (intravenous infusion)
- What this could lead to
- If it works, this could point toward a treatment that slows nerve damage and improves muscle strength in people with multifocal motor neuropathy.
- What could go wrong
- This is a very early, small Phase 1b study with no placebo group, so results may not prove effectiveness. The drug may cause side effects or fail to show meaningful benefit.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIFOCAL MOTOR NEUROPATHY (MMN) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Aversi Clinic LTD
RECRUITINGTbilisi, 160, Georgia
-
Jo Ann Medical Center
RECRUITINGTbilisi, Georgia
-
S. Khechinashvili University Clinic, Ltd.
RECRUITINGTbilisi, Georgia
More trials for these conditions
Other studies related to the condition(s) this trial covers.